Skip to content

Wired News Engine – Lifestyle

Author: Walden Biosciences Securities Corporation

Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease

September 15, 2026

All content ©2025 Tork Media
All Rights Reserved. For more information on this site, please read our Privacy Policy, Terms of Service, Cookie Policy, and Ad Choices.